Cure My Disease

Don't miss your cure!

 Log in / Sign up

Carb showdown: which diet best controls type 1 diabetes?

NCT ID NCT03761186

Disease control Sponsor: Anneli Björklund Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study tests how different amounts of dietary carbohydrates affect insulin needs and blood sugar control in adults with type 1 diabetes. Participants are randomly assigned to one of three diets: a traditional diet with 50-60% of calories from carbs, a moderately low-carb diet (30-40% carbs), or a strictly low-carb diet (15-20% carbs). The main goal is to see if lower-carb diets reduce the amount of insulin needed while maintaining good metabolic control over six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
three diets with different carbohydrate levels: traditional (50-60% carbs), moderately low (30-40% carbs), and strictly low (15-20% carbs)
What this could lead to
If successful, this trial could provide clear dietary guidance for people with type 1 diabetes, potentially reducing insulin needs and improving blood sugar control.
What could go wrong
This is a relatively small, single-center study with 103 participants, and dietary adherence can be challenging. Results may not apply to everyone with type 1 diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

103 people

The number who actually took part.

Started

Dec 2018

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * To have had type 1 diabetes for at least 1 year * Age \>=20 years old Exclusion Criteria: * Cardiovascular disease NYHA class IIIB or more * Kidney disease \> stadium 3 * Liver disease, alanine aminotransferase (ALAT) ≥ 2 µkat/L, * BMI \< 18.5 kg/m\^2 * c-peptide ≥ 0.3 nmol/l * Pregnant/breastfeeding women, women that plan to get pregnant during study period * Other circumstances, which, according to the examiner, make it difficult for an individual to participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE1DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE1DIABETES

Contacts and locations

Locations

  • Center for Diabetes, Academic Specialistcenter

    Stockholm, 11365, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.